SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2007
SkyePharma PLC
SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.
Form 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______
FOR IMMEDIATE RELEASE
Addendum to results announcement
SkyePharma PLC (LSE:SKP; NASDAQ: SKYE), LONDON, ENGLAND, 1 May 2007
This announcement is to correct a minor typographical error on the results
announcement of 26 April 2007.
Whilst the total figures for earnings per share for 2006 were correctly stated
in the original announcement, the split between pre-exceptional and exceptional
earnings per share for 2006 was incorrectly stated on the face of the profit and
loss account. The figures were correctly stated in Note 6 to the original
announcement, an extract of which is set out below:
Earnings per share
Year to Year to
31 December 2006 31 December 2005
(restated)
Continuing operations
Loss per Ordinary Share before exceptional items (3.4)p (2.5)p
Exceptional items 0.9p (0.8)p
_____ _____
Basic and diluted loss per Ordinary Share (2.5)p (3.3)p
_____ _____
Continuing and discontinued operations
Loss per Ordinary Share before exceptional items (6.4)p (4.7)p
Exceptional items (4.0)p (3.4)p
_____ _____
Basic and diluted loss per Ordinary Share (10.4)p (8.1)p
_____ _____
For further information please contact:
SkyePharma PLC
Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer +44 207 491 1777
Peter Grant, Finance Director
Financial Dynamics (London enquiries)
David Yates / Deborah Scott +44 207 831 3113
Trout Group (US enquiries)
Christine Labaree / Seth Lewis +1 617 583 1308
About SkyePharma PLC
Using its proprietary drug delivery technologies, SkyePharma develops new
formulations of known molecules to provide a clinical advantage and life-cycle
extension. The Group has ten approved products in the areas of oral, inhalation
and topical delivery. The Group's products are marketed throughout the world by
leading pharmaceutical companies. For more information, visit
www.skyepharma.com.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SkyePharma PLC
By: /s/ John Murphy
Name: John Murphy
Title:
Company Secretary
Date: May 01, 2007